Parallel designs (total variance) [Power / Sample Size]

posted by Helmut Homepage – Vienna, Austria, 2007-07-20 18:29 (6902 d 22:50 ago) – Posting: # 917
Views: 31,946

Dear Nav!

❝ I have data from a parallel pilot study and am using that to estimate the sample size for a pivotal study. The formula that I am using requires an estimate of the inter subject variability which I don't have. I have the total variability (sqrt(MSE)). Is there a way to estimate intersubject variability from a parallel design or would it be correct to use the total variability instead?


Hhm, yes you have the total variability (inter- + intra-subjects); the same will be true for your pivotal study. I don’t get your point of trying to estimate inter-subject variability from total. Which formula are you referring to?

❝ Would it be correct to estimate inter-subject var as sd/mean for test and reference separately and then take the average?


❝ And one last question, how correct is it to take 60% of inter subject (calculated as sd/mean) to be the intrasubject variability?


I don’t think so (both questions).

For an example please have a look at
Chow SC, Wang H. On Sample Size Calculation in Bioequivalence Trials. J Pharmacokin Pharmacodyn. 2001;28(2):155-69.
and Errata given at
J Pharmacokin Pharmacodyn. 2002;29(1):101-2.

You will also need two letters to the editor:
Hauschke D. A Note on Sample Size Calculation in Bioequivalence Trials. J Pharmacokin Pharmacodyn. 2002;29(1):89-94.
Blood P. Sample Size Calculation in Bioeqivalence Trials. J Pharmacokin Pharmacodyn. 2002;29(1):95-7.
H Wang H, SC Chow SC. Authors’ Response. J Pharmacokin Pharmacodyn. 2002;29(1):99.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
101 visitors (0 registered, 101 guests [including 22 identified bots]).
Forum time: 17:20 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5